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Abstract
Background The aim of this proof-of-concept study was to show that the liver segmental volume and attenuation ratio 
(LSVAR) improves the detection of significant liver fibrosis on portal venous CT scans by adding the liver vein to cava 
attenuation (LVCA) to the liver segmental volume ratio (LSVR).
Material and methods Patients who underwent portal venous phase abdominal CT scans and MR elastography (reference 
standard) within 3 months between 02/2016 and 05/2017 were included. The LSVAR was calculated on portal venous CT 
scans as LSVR*LVCA, while the LSVR represented the volume ratio between Couinaud segments I-III and IV-VIII, and 
the LVCA represented the density of the liver veins compared to the density in the vena cava. The LSVAR and LSVR were 
compared between patients with and without significantly elevated liver stiffness (based on a cutoff value of 3.5 kPa) using 
the Mann–Whitney U test and ROC curve analysis.
Results The LSVR and LSVAR allowed significant differentiation between patients with (n = 19) and without (n = 122) sig-
nificantly elevated liver stiffness (p < 0.001). However, the LSVAR showed a higher area under the curve (AUC = 0.96) than 
the LSVR (AUC = 0.74). The optimal cutoff value was 0.34 for the LSVR, which detected clinically increased liver stiffness 
with a sensitivity of 53% and a specificity of 88%. With a cutoff value of 0.67 for the LSVAR, the sensitivity increased to 
95% while maintaining a specificity of 89%.
Conclusion The LSVAR improves the detection of significant liver fibrosis on portal venous CT scans compared to the LSVR.
Keywords Computed tomography · Liver cirrhosis · Fibrosis · Computer-assisted image processing · Computer-assisted 
diagnosis
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Abbreviations
AUC  Area under the curve
CLD  Chronic liver disease
CRL-R  Caudate–right lobe ratio
HCC  Hepatocellular carcinoma
IVC  Inferior vena cava
LIMA-FS  Liver imaging morphology and attenuation 
fibrosis score
LSVR  Liver segmental volume ratio
LSVAR  Liver segmental volume and attenuation ratio
LVCA  Liver vein to cava attenuation
MDCT  Multidetector computed tomography
MR  Magnetic resonance
ROC  Receiver operating characteristics
Introduction
Early detection of clinically significant liver fibrosis is of 
utmost importance in preventing disease progression and 
the development of hepatocellular carcinoma (HCC) [1]. 
In addition to leading to improved patient prognosis, early 
prevention and treatment might lower healthcare costs [2]. 
Ultrasound and magnetic resonance (MR) elastography 
allow noninvasive grading of significant liver fibrosis in 
patients with suspected chronic liver disease [3], but patients 
often present with already advanced liver fibrosis and cirrho-
sis. Many CT scans in radiology departments are performed 
for a multitude of reasons unrelated to chronic liver disease 
(CLD). Good and reliable quantitative liver fibrosis scores 
obtainable from routine portal venous CT scans are therefore 
highly desirable.
Most CT methods for detecting liver fibrosis are qualita-
tive and therefore reader-dependent techniques [4]. Several 
quantitative methods allow for the detection of advanced 
fibrosis on CT scans, such as the caudate–right lobe ratio 
(CRL-R) and liver vein diameters [5, 6], CT texture analysis 
[7, 8], liver surface nodularity [9, 10], splenic volume and 
liver segmental volume ratio (LSVR) [11, 12]. Recently, 
improved predictions of significant liver fibrosis were 
achieved on abdominal CT scans with the new liver imag-
ing morphology and attenuation fibrosis score (LIMA-FS), 
which is a combination of the CRL-R with a liver vein to 
cava attenuation (LVCA) score [13].
Since the LVCA is simple and easy to calculate, we 
hypothesized that the LVCA might also increase the perfor-
mance of the LSVR in detecting liver fibrosis. The aim of 
this proof-of concept study was to show that the detection 
of significant liver fibrosis on abdominal CT scans may be 
improved with the use of the liver segmental volume and 
attenuation ratio (LSVAR), which is as a combination of the 
LVCA and LSVR.
Materials and methods
Study population
This prospective cross-sectional study was approved by the 
institutional review board (Kantonale Ethikkommission 
Bern, IRB number 282-15) and conducted after obtaining 
written informed consent from the patients.
The inclusion criteria were age between 18 and 70 years 
as well as a portal venous phase abdominal CT scan and 
gradient echo-based MR elastography exam (reference 
standard) performed within 3 months. The indications 
for CT scans were trauma (n = 22), search for inflamma-
tion (n = 34), ileus (n = 13), nonliver tumor (n = 43), HCC 
screening (n = 15) and abdominal pain (n = 14). The exclu-
sion criteria included solid liver lesions > 2 cm, portal vein 
thrombosis, prior liver surgery and transplantation. After 
applying the inclusion and exclusion criteria, 148 consecu-
tive patients were included from 02/2016 to 05/2017.
Seven patients were excluded because of technical fail-
ure during MR elastography (n = 6) or early cessation of 
the MR exam due to claustrophobia (n = 1), resulting in a 
total study population of 141. A total of 122 patients had a 
liver stiffness < 3.5 kPa, while 19 patients had a stiffness of 
3.5 kPa, consistent with clinically significant liver fibrosis 
(corresponding to a fibrosis stage ≥ F2) (Fig. 1). Clinical 
information (BMI, comorbidities, smoking and alcohol 
habits) and laboratory test results (liver enzymes, coagu-
lation results and APRI) were recorded. Data from this 
patient population have already been published in other 
research studies [13–15].
CT imaging and postprocessing
CT scans were acquired on Siemens Somatom Definition 
Flash, Definition Edge (Siemens Healthineers, Erlangen, 
Germany) and Philips Brilliance 64 (Philips, Best, Nether-
lands) scanners with a pitch of 0.8 and a detector collima-
tion of 0.6. The acquisitions were performed with atten-
uation-based kV selection and automated mAs adaption 
using references of 100 kVp and 150 mAs. Portal venous 
phase acquisitions were performed 75 s after the injection 
of 110 ml of contrast agent (Ultravist® 370, Bayer AG, 
Leverkusen, Germany, Xenetix® 300, Guerbet, Villepinte, 
France, Iomeron® 300, Bracco, Milan, Italy, flow rate 
2 ml/s). One-millimeter axial slices were reconstructed 
with an increment of 1 mm in a liver parenchyma window 
using a vendor-specific iterative reconstruction algorithm 
(Saphire level 3 and iDose level 3).
CT images were evaluated by a radiologist (A.T.H.) 
with 7  years of experience on a dedicated reading 
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workstation (MDCC-6230, Barco, Kortrijk, Belgium) 
using the Picture Archiving and Communication System 
(PACS) (IDS7, SECTRA, Linköping, Sweden). The LVCA 
was determined by comparing the attenuation of the liver 
veins to the inferior vena cava (IVC) as described previ-
ously [13]. The LVCA is an ordinal score based on the 
density of the liver veins 1 cm proximal to the liver vein 
confluence compared with the vena cava 1 cm below the 
liver vein confluence. Assessment is based on a visual 
comparison of the liver veins and the inferior vena cava. 
In the case of similar attenuation, a region of interest is 
drawn in the liver veins, 1 cm proximal to the liver vein 
confluence and in the inferior vena cava 1 cm below the 
liver vein confluence. If the mean density of the three 
liver veins is within ± 20 HU of the density of the vena 
cava, the liver veins are defined as isoattenuating to the 
vena cava (LVCA score 2). Otherwise, the liver veins are 
called hyperattenuating (LVCA score 1) or hypoattenuat-
ing (LVCA score 3). If the liver veins are not contrasted at 
all, this results in an LVCA score of 4 (Fig. 2).
Liver volumetry was performed using the liver analysis 
application in Philips Intellispace Portal (Philips, Best, Neth-
erlands) volumetry software by a second radiologist (C.M.) 
with 2 years of experience in liver imaging. Liver contours 
were recognized by the software and manually corrected if 
needed. In a next step anatomical landmarks (inferior vena 
Fig. 1  Patient flowchart. A total of 152 patients with portal venous 
abdominal CT scans were included in the study. MRI scans from six 
patients were excluded. MRI scans from 146 patients were included 
in the analysis and separated based on their liver stiffness (< 3.5 kPa, 
n = 122 and ≥ 3.5  kPa, n = 24). All CT fibrosis scores as well as 
splenic volumes were assessed for all patients
Fig. 2  Liver vein to cava attenuation (LVCA) classification. a Cat-
egory 1: liver veins are hyperattenuated compared to the inferior 
vena cava (IVC), b 2: liver veins are isoattenuated, c 3: liver veins are 
hypoattenuated, and d 4: liver veins have no visible contrast. LVCA 
liver vein to cava attenuation, IVC inferior vena cava
 Abdominal Radiology
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cava, right and left portal bifurcation, right and mid hepatic 
vein, umbilical fissure, tip of the left liver, superficial and 
deep ligamentum venosum) were defined based on the land-
marks the software calculated the volume of each liver seg-
ment as well as the sum for volume for the left (segments 
I-III) and right (segments IV to VIII) liver lobes. The LSVR 
then was calculated as described in the literature [12]:
 The LSVAR was then calculated as LSVR * LVCA (Fig. 3). 
The total time to determine the LSVAR was approximately 
ten minutes per patient, depending on the manual adjust-
ments for liver organ margins.
To compare the performance of semiautomated and 
manual segmentation, segments I to III and segments IV 
to VIII were segmented manually in a second analysis 
using the region growing tool in all patients with a liver 
stiffness > 2.8 kPa.
MR imaging technique and imaging analysis
The patients were examined with a 3-T MR system (Verio, 
Siemens Healthineers, Erlangen, Germany) in a fasting state 
(> 6 h). A pneumatic driver (Resoundant, Rochester, MN, 
LSVR =
Volume segments I − III
Volume segments IV − VIII
USA) was placed on the right upper quadrant to transmit 
shear waves by continuous acoustic vibrations at 60 Hz. 
The liver shear modulus in kPa in the right upper liver lobe 
was determined with a gradient echo-based elastography 
sequence (WIP package 622 provided by Siemens Health-
ineers, 3 single-slice acquisitions with 5  mm slice thick-
nesses) using the 95% confidence map of stiffness. The MR 
elastography images were read by a radiologist who was 
blinded to the results of the CT scans. MR elastography-
based stiffness assessments were used as a reference stand-
ard for liver fibrosis graduation. A cutoff value of ≥ 3.5 kPa 
for clinically significant liver fibrosis was used, correspond-
ing to a Metavir stage ≥ F2 in histology and a cutoff of 8 kPa 
in transient elastography (FibroScan®) [16].
Statistical analysis
Analysis was performed with the statistical software pack-
age R version 3.4.1 [17] and GraphPad Prism (Version 7.1, 
GraphPad Software Inc, CA, USA). ROC curve analysis was 
used to compare the performances of CT fibrosis scores to 
predict significantly elevated liver stiffness. Areas under the 
curves (AUCs) and 95% confidence intervals were calcu-
lated. Cutoff values were chosen based on Youden’s index. 
Clinical parameters were compared between patient groups 
using the Mann–Whitney U test for continuous variables and 
Fig. 3  Patient examples with and without clinically significant 
increased liver stiffness demonstrating the LSVR and LSVAR. On 
the left side, CT images from a cirrhotic patient (liver stiffness of 
6.7 kPa) with hypertrophic left and caudate lobes as well as noncon-
trasted liver veins (LVCA 4) are shown, resulting in an LSVR = 0.2 
and LSVAR = 0.8. On the right side, CT images from a patient with 
normal liver stiffness are shown (2.2  kPa). All liver fibrosis meas-
ures were within normal limits; LSVR = 0.22, LSVAR = 0.22 and 
LVCA = 1. LVCA liver vein to cava attenuation, LSVR liver segmental 
volume ratio, LSVAR liver segmental volume and attenuation ratio
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Fisher’s exact test for categorical variables. To determine 
the interrater reliability of volumetry measurements, another 
radiologist (J.H., 3 years of experience) measured segmental 
volumes in 20 randomly selected patients, and one-way con-
sistency intraclass correlation coefficients (ICCs) were then 
calculated for the LVCA, LSVR and LSVAR. To compare 
the performance of semiautomated and manual segmenta-
tion, ROC curve analysis was repeated using the LSVR and 
LSVAR based on the manual segmentation. For ICC results, 
classifications from 0.4 to 0.59 are considered as fair, those 
from 0.6 to 0.74 as good, and those from 0.75 to 1.00 are 
considered excellent [18].
Results
Patient characteristics
Based on MRE there were 90 patients with a nor-
mal liver stiffness (< 2.5  kPa), 20 patients with liver 
stiffness ≥ 2.5–2.9 kPa (normal or chronic inflammation), 12 
patients with liver stiffness ≥ 2.9–3.5 kPa (F1-2), 5 patients 
with liver stiffness ≥ 3.5–4 kPa (F2-3), 4 patients with liver 
stiffness ≥ 4–5 kPa (F3-4) and 10 patients with liver stiff-
ness ≥ 5 kPa (F4). The patient characteristics are shown 
in Table 1. Patients with elevated liver stiffness ≥ 3.5 kPa 
had significantly higher levels of liver enzymes (AST 37.0 
[31.5–68.0] vs. 22.0 [19.3–25.8], p < 0.001, ALT 30.0 
[25.0–46.0] vs. 23.0 [17.0–35.8], p = 0.015; GGT 109.0 
[70.0–150.0] vs. 23.0 [17.0–38.0], p < 0.001) as well as 
bilirubin (19 [13.5–35.0] vs. 7.0 [5.0–12.0], p < 0.001) and 
APRI (0.9 [0.6–29] vs. 0.2 [0–0.3], p = 0.033) but lower 
Quick values (71.5 [63.2–90.5] vs. 100.0 [99.0–100.0], 
p < 0.001). Two patients had ascites. There were more smok-
ers (58% vs. 16%, p < 0.001) and patients who consumed 
alcohol daily (72% vs. 6%, p < 0.001) among the patients 
with elevated liver stiffness.
Of the 19 patients with elevated liver stiffness (shear mod-
ulus ≥ 3.5 kPa), 18 had known liver fibrosis (3 patients with 
a histology fibrosis grade F2, 6 patients with a grade of F3 
Table 1  Patient characteristics
Values are reported as the median and interquartile range or the absolute number (n) with the percentage of 
study group. P values were calculated using the Mann–Whitney U test or Fisher’s exact test, as appropriate. 
Comparisons between the two patient groups are indicated with * if p < 0.05 and ** if p < 0.001
BMI body mass index, PDFF proton density fat fraction, AST aspartate aminotransferase, ALT alanine ami-
notransferase, GGT gamma-glutamyltransferase, APRI aspartate aminotransferase-to-platelet ratio index
Normal to slightly 
increased liver stiffness
(shear modu-
lus < 3.5 kPa)
n Significantly 
increased liver stiff-
ness
(shear modu-
lus ≥ 3.5 kPa)
n p–value
Age, years 53.4 [42.9–62.3] 122 55.9 [54.0–66.1] 19 0.134
Male, % 62 (51%) 122 16 (84%) 19  < 0.001**
Shear modulus, kPa 214 [187–254] 122 481 [378–574] 16  < 0.001**
Tobacco use, n (%) 19 (16%) 121 11 (58%) 19  < 0.001**
Alcohol consumption, n (%) 8 (6%) 121 13 (72%) 18  < 0.001**
Diabetes, n (%) 8 (7%) 120 7 (37%) 19 0.001*
Hypertension, n (%) 26 (22%) 121 9 (47%) 19 0.023*
BMI, kg/m2 25.3 [22.9–29.0] 122 27.7 [25.0–33.4] 19 0.072
PDFF, % 7% [5–11%] 121 9 [6–17] 18 0.710
AST, U/l 22.0 [19.3–25.8] 54 37.0 [31.5–68.0] 15  < 0.001**
ALT, U/l 23.0 [17.0–35.8] 70 30.0 [25.0–46.0] 15 0.015*
GGT, U/l 23.0 [17.0–38.0] 61 109.0 [70.0–150.0] 16  < 0.001**
Alkaline phosphatase, U/l 72.0 [54.0–83.5] 55 97.0 [64.5–118.5] 15 0.041*
Bilirubin, μmol/l 7.0 [5.0–12.0] 47 19 [13.5–35.0] 15  < 0.001**
Albumin 36 [34.8–38.0] 40 35 [30.0–38.0] 16 0.405
Dyslipidemia 13 (11%) 121 3 (16%) 19 0.457
Quick, % 100.0 [99.0–100.0] 59 71.5 [63.2–90.5] 16  < 0.001**
APRI 0.2 [0–0.3] 30 0.9 [0.6–29] 9 0.033*
Creatinine, μmol/l 76.0 [67.0–91.0] 89 71.0 [65.0–82.0] 18 0.326
Chronic renal insufficiency 1 (1%) 120 1 (5%) 19 0.256
 ≥ 1 medication(s) per day 29 (24%) 121 15 (79%) 19  < 0.001**
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and 9 patients with a grade of F4 on histology or clinically 
established diagnosis of liver cirrhosis), while chronic liver 
disease was not known in 1 patient who was lost to follow-
up (cancer patient without liver metastasis). The etiology of 
liver disease in those patients was as follows: viral hepatitis 
(n = 9), alcohol induced liver disease (n = 2), NAFLD/NASH 
(n = 3), cryptogenic liver cirrhosis (F4) on histology (n = 1) 
and unknown in the one patient who was lost to follow-up. 
The median time interval between biopsy and MRE was 
18 months [IQR 3.5–26.5 months]. The median MRE ROI 
size was 3184  mm2 [IQR 2129–4643  mm2].
Of the 122 patients without elevated liver stiffness (shear 
modulus < 3.5 kPa), 2 had liver biopsy with a diagnosis of 
NAFLD/NASH (1 patient with a histology fibrosis grade 
of F1 and one patient with a grade of F2), 5 patients had 
chronic viral hepatitis without known liver fibrosis, and the 
remaining 115 patients had no known chronic liver disease.
Liver fibrosis detection
The LSVR, LVCA and LSVAR were all significantly ele-
vated in patients with liver stiffness ≥ 3.5 kPa, as shown in 
Table 2 and illustrated in violin plots in Fig. 4. In the ROC 
curve analysis, the LSVR (AUC = 0.74) showed slightly 
worse performance than splenic volume (AUC = 0.83), but 
clearly better performance when combined with the LVCA 
(AUC = 0.88) to obtain the LSVAR (AUC = 0.96) (Fig. 5). 
The optimal cutoff value for the LSVR was 0.34, and this 
value predicted clinically significant liver fibrosis with a sen-
sitivity of 53% and a specificity of 88% (10 true-positives, 
107 true-negatives, 15 false-positives and 9 false-negatives). 
The optimal cutoff value for the LSVAR was 0.67, and this 
value predicted clinically significant liver fibrosis with a sen-
sitivity of 95% and a specificity of 89% (18 true-positive, 
109 true-negatives, 13 false-positives and 1 false-negative). 
Further details are shown in Table 3.   
Comparison of semiautomated and manual 
segmentation
The LVCA score was determined in a few seconds in most 
cases with visual assessment and was still determined in less 
than one minute in cases with measurements of Hounsfield 
units. The LSVR and LSVAR were calculated in 10 min 
using the semiautomated method. In the second analysis 
with manual segmentation of the liver segments I–III and 
IV–VIII, the reconstruction time was much longer and took 
up to 30 min for the LSVR and LSVAR. However, the results 
remained unchanged with an AUC = 0.74 for the LSVR and 
an AUC = 0.96 for the LSVAR to predict significant liver 
fibrosis.
Interobserver reliability
Interobserver reliability within our group was excellent for 
the LVCA (ICC = 0.92), LSVR (ICC = 0.96) and LSVAR 
(ICC = 0.97).
Discussion
This study shows that the LSVAR improves the detection 
of significant liver fibrosis on portal venous CT scans by 
combining the LVCA with the LSVR. The LSVAR may be 
easily calculated based on standard liver segmental volu-
metry, and the LVCA can be obtained by simply compar-
ing the liver vein density to the density of the inferior vena 
cava on any portal venous abdominal CT scan.
A high LVCA reflects delayed enhancement of the liver 
veins compared to the systemic enhancement of the inferior 
vena cava. Delayed microperfusion of the liver in chronic 
liver disease might therefore be a possible explanation 
for the high LVCA score in patients with significant liver 
Table 2  Descriptive statistics 
for fibrosis scores
Values are reported as the median and interquartile range. P values were calculated using the Mann–Whit-
ney U test. Comparisons between the two patient groups are indicated with * if p < 0.05 and ** if p < 0.001
IQR inter quartile range, LVCA liver vein to cava attenuation, LSVR liver segmental volume ratio, LSVAR 
liver segmental volume and attenuation ratio
Median [IQR] Normal to slightly 
increased liver stiffness
(shear modu-
lus ≤ 3.5 kPa)
n Clinically significant 
increased liver stiffness
(shear modu-
lus ≥ 3.5 kPa)
n p–value
LVCA 1.00 [1.00–2.00] 122 4.00 [3.00–4.00] 19  < 0.001**
LSVR 0.27 [0.22–0.31] 122 0.38 [0.26–0.54] 19  < 0.001**
LSVAR 0.33 [0.25–0.48] 122 1.05 [0.85–2.14] 19  < 0.001**
I–III, ml 333 [261–396] 122 449 [362–650] 19 0.002*
IV–VIII, ml 1237 [1088–1427] 122 1160 [1008–1579] 19 0.864
Total liver volume, ml 1588 [1371–1844] 122 1743 [1427–2078] 19 0.121
Splenic volume, ml 229 [172–303] 115 442 [333–669] 19  < 0.001
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fibrosis. Reduced liver perfusion in chronic liver disease 
has already been investigated by other groups [19, 20]. As 
the portal venous perfusion decreases, the arterial perfusion 
fraction increases, and total liver perfusion is delayed in 
patients with higher degrees of fibrosis [21]. Zissen et al. 
reported a significant decrease in the liver-to-aorta ratio in 
Fig. 4  Violin plots comparing patients with and without elevated 
liver stiffness. Distribution of the results for the LSVR (a), splenic 
volume (b), LSVAR (c), and LVCA (d) are shown for patients with 
a liver stiffness of < 3.5 and ≥ 3.5 kPa. ROC receiver operating char-
acteristic, AUC area under the (ROC) curve, LVCA liver vein to cava 
attenuation, LSVR liver segmental volume ratio, LSVAR liver segmen-
tal volume and attenuation ratio
Fig. 5  ROC curve analysis. ROC curves of the quantitative CT 
parameters for distinguishing between patients with and with-
out elevated liver stiffness (shear modulus < 3.5  kPa vs. ≥ 3.5  kPa) 
are shown. AUC values as well as optimal cutoff values based on 
Youden’s index with sensitivity and specificity are indicated. An 
LSVAR cutoff of 0.42 or higher provides a sensitivity of 92% and a 
specificity of 70%. ROC receiver operating characteristic, AUC area 
under the (ROC) curve, LVCA liver vein to cava attenuation, LSVR 
liver segmental volume ratio, LSVAR liver segmental volume and 
attenuation ratio
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cirrhotic patients compared with patients without CLD [22], 
while Koiwahara et al. demonstrated a decreasing parenchy-
mal density (ΔHU precontrast to portal venous phase) in 
patients with higher degrees of chronic liver damage [23].
The LSVR is calculated based on liver segmental volume-
try and was initially described by Furusato Hunt et al. [12] 
based on known liver remodeling in chronic liver disease 
including volume loss in Couinaud the segments IV-VIII and 
hypertrophy of segments I-III. The LSVR was significantly 
increased in patients with liver cirrhosis (LSVR = 0.55) 
compared with healthy controls (LSVR = 0.27). Com-
pared to Furosato Hunt et al., we found exactly the same 
median LSVR value in patients with liver stiffness < 3.5 kPa, 
while the LSVR in patients with increased liver stiffness 
(≥ 3.5 kPa) was slightly lower in our study. This may be 
explained by the fact that a stiffness of 3.5 kPa on MR elas-
tography corresponds to a histologic fibrosis score of F2 or 
higher, while Furusato Hunt et al. included only patients 
with cirrhosis (F4). Another liver volumetry study showed 
increased LSVR values in patients with liver fibrosis includ-
ing those in intermediate stages and revealed values of 0.25 
for stage F1, 0.33 for stage F2, 0.39 for stage F3 and 0.56 
for stage F4, which reflects the range of our results [11]. In 
another study by the same group, the diagnostic accuracy 
was slightly higher, discriminating liver fibrosis stage F0-1 
from stage F2-4 with an AUC of 0.85 (the AUC was 0.74 
in our study). This might be explained by the larger num-
ber of patients with advanced fibrosis [24] in the study by 
Pickhardt et al., while the present study included a large 
number of patients without elevated liver stiffness. Pick-
hardt et al. achieved an even higher diagnostic accuracy for 
significant fibrosis (≥ F2) with an AUC of 0.91 by combin-
ing the LSVR with six other CT features (LSN, periportal 
space distance, ratio of the left to right portal vein diameters, 
total liver volume, splenic volume and texture analysis). By 
finally adding the APRI and FIB-4 score, the AUC could 
be increased to 0.93, which is similar to the combination of 
LVCA and LSVR in our study (AUC = 0.96).
Manual segmentation of liver segments I-III and IV-VIII 
with the region growing tool did not improve the predictive 
value of the LSVR and LSVAR to detect significant liver 
fibrosis compared with the semiautomated segmentation. We 
therefore conclude that the faster, semiautomated method is 
sufficient to determine the LSVR and LSVAR. Therefore, 
the LSVR may be calculated in approximately 10 min, and 
the additional LVCA is determined easily in less than 10 s to 
calculate the LSVAR. New AI-based algorithms may allow 
even faster quantification of liver segmental volumes in the 
near future.
In our study, splenic volume also allowed for the pre-
diction of significantly elevated liver stiffness but had infe-
rior performance to the LVSAR. Measurements of splenic 
diameter have already been investigated in the 1980s [25]. 
More recently, splenic volume was shown to detect signifi-
cant liver fibrosis (≥ F2) with AUC values of 0.85 and 0.76 
found by Pickhardt et al. [11, 24], while Lotan et al. found 
that the splenic volume discriminated between patients with 
advanced (F2) and severe (F3-F4) fibrosis with an AUC of 
0.80 [26], which is within the same range of our presented 
results (AUC = 0.83). Notably, several nonhepatic factors 
can cause splenomegaly, and these factors should be taken 
into account, especially in the setting of CT exams per-
formed for nonhepatic reasons.
The relatively small number of patients with significant 
fibrosis constitutes a limitation of this paper. The smaller 
group of 15% with significantly increased liver stiffness and 
the larger group of 85% without significantly increased liver 
stiffness represent the spectrum of our center. Therefore, 
there may be a spectrum bias if the results are compared to 
those from other centers. In this proof-of-concept study, the 
LSVAR was a useful predictor for significant liver fibrosis 
on routine abdominal CT scans in a realistic scenario in a 
radiology department. The ability of the LVCA and LSVAR 
to differentiate between degrees of liver fibrosis should now 
be validated in a larger study including patients with biopsy-
proven fibrosis. Another limitation is possible confounding 
factors unrelated to liver fibrosis that may influence liver 
stiffness on MR elastography, and the LVCA, such as inflam-
mation in alcoholic and nonalcoholic steatohepatitis [27]. 
However, MR elastography has been proven to show an 
excellent correlation with histological fibrosis grade [28] 
and liver biopsy also has its limitations with important inter-
rater variability and the risk of sampling error [29]. Using 
a cutoff for liver stiffness of 3.5 kPa or higher, observed 
changes are so distinct that elevated liver stiffness cannot 
be explained by inflammation alone. The LVCA might be 
influenced in cases of contrast reflux in patients with right 
Table 3  Diagnostic accuracy for fibrosis scores
The performance to detect significant liver fibrosis for each score is 
presented in terms of true-positive, true-negative, false-positive and 
false-negative results. Two different cutoff values for LSVAR are 
shown. The higher cutoff value is optimized according to Youden’s 
index in the ROC curve analysis, and the lower cutoff value is opti-
mized for a minimal number of false-negatives
LSVR liver segmental volume ratio, LSVAR liver segmental volume 
and attenuation ratio, LVCA liver vein to cava attenuation, ROC 
receiver operating characteristic
Score LSVR LSVAR 
cutoff 
0.67
LSVAR 
cutoff 
0.47
LVCA Splenic 
volume
True-positive 10 18 19 14 14
True-negative 107 109 89 111 109
False-positive 15 13 33 11 13
False-nega-
tive
9 1 0 5 5
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ventricular dysfunction or tricuspid regurgitation. We there-
fore excluded the patient with cardiac dysfunction, and 
there were no further patients with known heart failure in 
our study population. Contrast reflux into the IVC is mostly 
seen during the arterial phase; it is therefore important to 
calculate the LVCA and LSVAR only during correctly timed 
portal venous phases of the liver. The LVCA was determined 
visually in most patients by comparing the density of the 
liver vein with that of the vena cava. Only in unclear cases 
the densities of the liver veins and the vena cava were meas-
ured, while a difference of 20 HU or more was defined as 
significantly different density between the liver veins and the 
vena cava. This visual interpretation makes determination of 
the LVCA very fast. However, since it is qualitative, it may 
be subject to reader interpretation. Nevertheless, with an 
ICC of 0.92, the interobserver reliability for the LVCA was 
excellent. Finally, the LVCA might be influenced by other 
factors such as a smaller diameter of liver veins in cirrhosis 
[13] or cardiac output and bolus timing. Such contrast timing 
differences might be reduced because the LVCA is a rela-
tive ratio and not an absolute measurement of Hounsfield 
units. In any case, the LVCA and LSVAR seem to be robust 
and reliable imaging biomarkers, which are fast and easy to 
calculate. While currently dedicated software solutions are 
needed for liver volumetry, new AI algorithms will over-
come this limitation.
In conclusion, the LSVAR improves the detection of 
significant liver fibrosis on portal venous CT scans com-
pared to the LSVR. This ratio is easy to calculate based on 
liver segmental volumetry and by comparing the enhance-
ment of the liver veins and the inferior vena cava. The 
use of the LSVAR allows for the accurate screening of 
portal venous CT scans to detect possible liver fibrosis 
with excellent interobserver reliability.
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